Skip to content

To see the efficacy of bakuchi compound and khadira kwatha with and without virechana karma in the the management of shwitra(Vitiligo).

A comparative clinical study to evaluate the efficacy of bakuchi compound and khadira kwatha with and without virechana in the management of shwitra w.s.r. to vitiligo.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019012
Enrollment
30
Registered
2019-05-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Bakuchi Compound, KhadiraKwatha and Virechana Karma : Group Aâ?? 15 Patients will be administered trial drugs- Bakuchi Compound 5gm twice a day and KhadiraKwatha40 ml twice daily orally

Sponsors

National Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients in the age group of 18 to 60 years of either sex. 2. Patient diagnosed as shwitra (vitiligo) on the basis of clinical features mentioned in Ayurveda texts. 3. Patients fit for virechana. 4. Patient with history of shwitra less than or equal to five years. 5. Patient willing to participate in the clinical trial.

Exclusion criteria

Exclusion criteria: 1. Patient with age group of less than 18 years and more than 60 years. 2. White anesthetic spots, which are characteristic of leprosy. 3. Patches in genital areawill be excluded from the study. 4. Vitiligo patches complicated with eczema. 5. Patients with evidence of malignancy, diabetes mellitus with complication, albinism. 6. Pregnant women and lactating mother. 7. Patient participated in any clinical trial within last six months.

Design outcomes

Primary

MeasureTime frame
Primary outcome: Assessment of changes in specific signs and symptoms of shwitra Secondary outcome: Any adverse effect in the values of haematological test and in clinical signs and symptoms.Timepoint: 60 days

Secondary

MeasureTime frame
Any adverse effect in the values of haematological test and in clinical signs and symptoms.Timepoint: 60 days

Countries

India

Contacts

Public ContactDr HML Meena

National Institute of Ayurveda

hari_mohan68@yahoo.co.in9461297017

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026